MCID: MSC003
MIFTS: 52

Muscular Atrophy

Categories: Bone diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Muscular Atrophy

MalaCards integrated aliases for Muscular Atrophy:

Name: Muscular Atrophy 12 43 15 71
Muscle Wasting 12 15
Skeletal Muscle Atrophy 71
Wasting - Muscle 12
Amyotrophia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:767
MeSH 43 D009133
NCIt 49 C94834
SNOMED-CT 67 88092000
UMLS 71 C0026846 C0541794

Summaries for Muscular Atrophy

MalaCards based summary : Muscular Atrophy, also known as muscle wasting, is related to spinal muscular atrophy, type ii and spinal muscular atrophy, distal, autosomal recessive, 1, and has symptoms including muscle weakness, myokymia and muscular fasciculation. An important gene associated with Muscular Atrophy is ATP2B3 (ATPase Plasma Membrane Ca2+ Transporting 3). The drugs Pioglitazone and Clobetasol have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, heart and kidney, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Muscular Atrophy

Diseases in the Muscular Atrophy family:

Progressive Muscular Atrophy

Diseases related to Muscular Atrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 830, show less)
# Related Disease Score Top Affiliating Genes
1 spinal muscular atrophy, type ii 35.3 SMN2 SMN1 NAIP
2 spinal muscular atrophy, distal, autosomal recessive, 1 35.3 SMN2 SMN1 IGHMBP2
3 spinal muscular atrophy, type iv 35.2 VAPB SMN2 SMN1 NAIP ASAH1
4 spinal muscular atrophy, type iii 35.1 SMN2 SMN1 SERF1A NAIP IGHMBP2
5 progressive muscular atrophy 35.0 VAPB TRPV4 SMN2 SMN1
6 spinal muscular atrophy, distal, autosomal recessive, 2 35.0 TRPV4 GARS1 BICD2
7 proximal spinal muscular atrophy 34.9 SMN2 SMN1 NAIP BICD2
8 spinal muscular atrophy with lower extremity predominance 34.9 DYNC1H1 BICD2
9 spinal muscular atrophy, type i 34.9 ZPR1 VRK1 SMN2 SMN1 SERF1A NAIP
10 survival motor neuron spinal muscular atrophy 34.6 ZPR1 VRK1 SMN2 SMN1 SERF1A NAIP
11 spinal muscular atrophy 34.1 ZPR1 VRK1 VAPB UBA1 TRPV4 TRIP4
12 autosomal dominant distal hereditary motor neuronopathy 33.9 TRPV4 IGHMBP2 BICD2
13 charcot-marie-tooth hereditary neuropathy 33.7 TRPV4 IGHMBP2 GARS1
14 motor neuron disease 33.4 VAPB SMN2 SMN1 PLEKHG5 NAIP GARS1
15 distal hereditary motor neuropathies 33.1 TRPV4 IGHMBP2 GARS1
16 spinal disease 33.0 SMN2 SMN1 NAIP
17 neuromuscular disease 32.9 TRPV4 SMN2 SMN1 NAIP IGHMBP2 GARS1
18 charcot-marie-tooth disease 32.7 VAPB TRPV4 SMN2 SMN1 PLEKHG5 IGHMBP2
19 motor peripheral neuropathy 32.5 TRPV4 IGHMBP2 GARS1 DYNC1H1 DNAJB2 BICD2
20 amyotrophic lateral sclerosis 1 32.4 VAPB SMN2 SMN1 NAIP IGHMBP2 DYNC1H1
21 neuropathy 31.7 TRPV4 IGHMBP2 GARS1 DYNC1H1
22 tooth disease 31.6 TRPV4 PLEKHG5 IGHMBP2 GARS1 DYNC1H1
23 congenital contractures 31.3 VRK1 UBA1 TRIP4
24 anterior horn cell disease 31.2 VRK1 UBA1 SMN2 SMN1 IGHMBP2
25 peripheral nervous system disease 31.2 TRPV4 SMN2 SMN1 GARS1
26 axonal neuropathy 31.2 VRK1 TRPV4 GARS1
27 genetic motor neuron disease 30.9 PLEKHG5 GARS1 DYNC1H1
28 muscular disease 30.7 SMN2 SMN1 NAIP IGHMBP2 GARS1 BICD2
29 hereditary motor and sensory neuropathy, type iic 30.3 TRPV4 GARS1
30 spinal and bulbar muscular atrophy, x-linked 1 13.0
31 spinal muscular atrophy, x-linked 2 12.9
32 spinal muscular atrophy, lower extremity-predominant, 1, autosomal dominant 12.9
33 spinal muscular atrophy, late-onset, finkel type 12.8
34 spinal muscular atrophy, distal, x-linked 3 12.8
35 scapuloperoneal spinal muscular atrophy 12.8
36 spinal muscular atrophy with progressive myoclonic epilepsy 12.8
37 spinal muscular atrophy, lower extremity-predominant, 2a, childhood onset, autosomal dominant 12.8
38 spinal muscular atrophy, distal, autosomal recessive, 3 12.7
39 spinal muscular atrophy, distal, autosomal recessive, 4 12.7
40 spinal muscular atrophy with congenital bone fractures 1 12.7
41 spinal muscular atrophy, jokela type 12.7
42 spinal muscular atrophy, lower extremity-predominant, 2b, prenatal onset, autosomal dominant 12.6
43 spinal muscular atrophy with congenital bone fractures 2 12.6
44 spinal muscular atrophy, distal, autosomal recessive, 5 12.6
45 autosomal dominant spinal muscular atrophy, lower extremity-predominant 2 12.6
46 neuronopathy, distal hereditary motor, type va 12.5
47 pelvic muscle wasting 12.5
48 autosomal dominant childhood-onset proximal spinal muscular atrophy 12.5
49 neuronopathy, distal hereditary motor, type viii 12.5
50 autosomal dominant adult-onset proximal spinal muscular atrophy 12.4
51 autosomal dominant proximal spinal muscular atrophy 12.4
52 spinal muscular atrophy, ryukyuan type 12.4
53 muscular atrophy, ataxia, retinitis pigmentosa, and diabetes mellitus 12.4
54 spinal muscular atrophy with respiratory distress type 2 12.4
55 spinal muscular atrophy, facioscapulohumeral type 12.4
56 spinal muscular atrophy, segmental 12.4
57 spastic paraplegia 20, autosomal recessive 12.3
58 amyotrophy, monomelic 12.3
59 spinal muscular atrophy-dandy-walker malformation-cataracts syndrome 12.3
60 generalized bulbospinal muscular atrophy 12.3
61 bulbospinal muscular atrophy of adult 12.3
62 bulbospinal muscular atrophy of childhood 12.3
63 muscular atrophy, malignant neurogenic 12.3
64 spinal muscular atrophy with mental retardation 12.3
65 spinal muscular atrophy with microcephaly and mental subnormality 12.3
66 primrose syndrome 12.2
67 adult progressive spinal muscular atrophy aran duchenne type 12.2
68 neuronopathy, distal hereditary motor, type i 12.2
69 charcot-marie-tooth peroneal muscular atrophy, x-linked, with aplasia cutis congenita 12.2
70 charcot-marie-tooth peroneal muscular atrophy and friedreich ataxia, combined 12.2
71 arthrogryposis spinal muscular atrophy 12.2
72 congenital benign spinal muscular atrophy dominant 12.2
73 obsolete: distal spinal muscular atrophy 12.2
74 spinal muscular atrophy associated with central nervous system anomaly 12.2
75 prenatal-onset spinal muscular atrophy with congenital bone fractures 12.2
76 proteasome-associated autoinflammatory syndrome 1 12.1
77 neuronopathy, distal hereditary motor, type viia 12.1
78 pontocerebellar hypoplasia, type 1a 12.0
79 neuronopathy, distal hereditary motor, type iia 12.0
80 spinal atrophy ophthalmoplegia pyramidal syndrome 12.0
81 mental retardation, x-linked, syndromic, cabezas type 12.0
82 hereditary motor and sensory neuropathy v 12.0
83 neuronopathy, distal hereditary motor, type vb 12.0
84 encephalopathy, progressive, with amyotrophy and optic atrophy 11.9
85 autosomal recessive distal hereditary motor neuronopathy 11.9
86 postpoliomyelitis syndrome 11.9
87 charcot-marie-tooth disease, demyelinating, type 1b 11.8
88 charcot-marie-tooth disease, x-linked dominant, 1 11.8
89 neuronopathy, distal hereditary motor, type iid 11.7
90 neuromyotonia and axonal neuropathy, autosomal recessive 11.7
91 distal hereditary motor neuropathy type 7 11.7
92 distal hereditary motor neuronopathy type 2 11.7
93 nathalie syndrome 11.7
94 neuronopathy, distal hereditary motor, type viib 11.7
95 autosomal recessive distal hereditary motor neuropathy 11.7
96 madras motor neuron disease 11.6
97 x-linked distal hereditary motor neuropathy 11.5
98 pontocerebellar hypoplasia type 1 11.5
99 distal hereditary motor neuronopathy type 7 11.5
100 pontocerebellar hypoplasia, type 1c 11.5
101 pontocerebellar hypoplasia 11.4
102 foot drop 11.4
103 allan-herndon-dudley syndrome 11.3
104 deafness, congenital, with vitiligo and achalasia 11.3
105 sptlc1-related hereditary sensory neuropathy 11.3
106 myotonic dystrophy 1 11.1
107 amyotrophy, hereditary neuralgic 11.1
108 ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia 11.1
109 spastic ataxia, charlevoix-saguenay type 11.1
110 spastic paraplegia 17, autosomal dominant 11.0
111 renpenning syndrome 1 11.0
112 spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1 11.0
113 neuronopathy, distal hereditary motor, type iib 11.0
114 neuronopathy, distal hereditary motor, type iic 11.0
115 myopathy, distal, tateyama type 11.0
116 ruijs-aalfs syndrome 11.0
117 myopathy, congenital, progressive, with scoliosis 11.0
118 3-methylcrotonyl-coa carboxylase deficiency 11.0
119 spinal cord disease 11.0
120 spastic paraplegia 8 11.0
121 adenylosuccinase deficiency 10.9
122 flynn-aird syndrome 10.9
123 myopathy, centronuclear, 1 10.9
124 oculopharyngodistal myopathy 1 10.9
125 tangier disease 10.9
126 agenesis of the corpus callosum with peripheral neuropathy 10.9
127 glycogen storage disease iv 10.9
128 richards-rundle syndrome 10.9
129 chylomicron retention disease 10.9
130 metachromatic leukodystrophy 10.9
131 muscular dystrophy, limb-girdle, autosomal recessive 5 10.9
132 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.9
133 leber optic atrophy and dystonia 10.9
134 desmosterolosis 10.9
135 muscular dystrophy, limb-girdle, autosomal recessive 4 10.9
136 spastic paraplegia 7, autosomal recessive 10.9
137 muscular dystrophy, limb-girdle, autosomal recessive 3 10.9
138 spastic paraplegia 31, autosomal dominant 10.9
139 lethal congenital contracture syndrome 3 10.9
140 chromosome 3q13.31 deletion syndrome 10.9
141 myopathy due to myoadenylate deaminase deficiency 10.9
142 miles-carpenter syndrome 10.9
143 syndromic x-linked intellectual disability cabezas type 10.9
144 myotonic disease 10.9
145 eating disorder 10.9
146 lama2-related muscular dystrophy 10.9
147 spastic paraplegia 3a 10.9
148 spastic paraplegia 11 10.9
149 genuine diffuse phlebectasia 10.9
150 spastic paraplegia 15 10.9
151 spastic paraplegia 5a 10.9
152 x-linked charcot-marie-tooth disease 10.9
153 becker's myotonia 10.9
154 thomsen's myotonia 10.9
155 scapuloperoneal syndrome, neurogenic, kaeser type 10.9
156 autosomal recessive disease 10.8
157 lateral sclerosis 10.8
158 o'sullivan-mcleod syndrome 10.8
159 muscular dystrophy 10.8
160 brown-vialetto-van laere syndrome 10.8
161 scoliosis 10.7
162 respiratory failure 10.7
163 hypotonia 10.7
164 primary lateral sclerosis, adult, 1 10.7
165 juvenile amyotrophic lateral sclerosis 10.7
166 myopathy 10.6
167 tremor 10.6
168 culler-jones syndrome 10.6 SMN2 SMN1
169 nephrolithiasis/osteoporosis, hypophosphatemic, 2 10.6 SMN2 SMN1
170 alkuraya-kucinskas syndrome 10.6
171 congenital amyoplasia 10.6
172 muscular dystrophy, duchenne type 10.6
173 mental retardation, autosomal dominant 13 10.6 DYNC1H1 BICD2
174 amelogenesis imperfecta, type ia 10.6 SMN2 SMN1
175 infant gynecomastia 10.5
176 gynecomastia 10.5
177 ataxia and polyneuropathy, adult-onset 10.5
178 dysphagia 10.5
179 poliomyelitis 10.5
180 charcot-marie-tooth disease intermediate type 10.5 GARS1 DNAJB2
181 charcot-marie-tooth disease/hereditary motor and sensory neuropathy 10.5 TRPV4 IGHMBP2 GARS1 DNAJB2
182 charcot-marie-tooth disease, axonal, type 2k 10.5 DYNC1H1 DNAJB2
183 mitochondrial dna depletion syndrome 3 10.5 TRIP4 BICD2
184 chronic kidney disease 10.4
185 charcot-marie-tooth disease, axonal, type 2e 10.4 TRPV4 IGHMBP2 GARS1 DYNC1H1 DNAJB2 BICD2
186 pulmonary disease, chronic obstructive 10.4
187 kidney disease 10.4
188 sensory peripheral neuropathy 10.4
189 early myoclonic encephalopathy 10.4
190 charcot-marie-tooth disease, axonal, type 2t 10.4 IGHMBP2 DNAJB2
191 polyneuropathy 10.4
192 myotonic dystrophy 10.4
193 amyotrophic lateral sclerosis 4, juvenile 10.4
194 myoclonic epilepsy of unverricht and lundborg 10.4
195 myasthenia gravis 10.3
196 distal arthrogryposis 10.3
197 huntington disease 10.3
198 aggressive systemic mastocytosis 10.3 ATP7A ASAH1
199 kearns-sayre syndrome 10.3
200 progressive muscular dystrophy 10.3
201 clubfoot 10.3
202 epilepsy 10.3
203 branchiootic syndrome 1 10.2
204 dentatorubral-pallidoluysian atrophy 10.2
205 ptosis 10.2
206 constipation 10.2
207 autonomic dysfunction 10.2
208 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 10.2
209 amyotrophic lateral sclerosis 2, juvenile 10.2
210 primary lateral sclerosis, juvenile 10.2
211 spastic paralysis, infantile-onset ascending 10.2
212 foix chavany marie syndrome 10.2
213 cystic fibrosis 10.2
214 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
215 fragile x syndrome 10.2
216 lung disease 10.2
217 47,xyy 10.2
218 asah1-related disorders 10.2
219 spasticity 10.2
220 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.2
221 autosomal dominant cerebellar ataxia 10.2
222 hereditary spastic paraplegia 10.2
223 paraplegia 10.2
224 neuroblastoma 10.2
225 limb-girdle muscular dystrophy 10.2
226 myoclonus 10.2
227 myotonia 10.2
228 end stage renal failure 10.2
229 charcot-marie-tooth disease, axonal, type 2q 10.2 PLEKHG5 DYNC1H1
230 atrial standstill 1 10.1
231 myositis 10.1
232 farber lipogranulomatosis 10.1
233 muscular dystrophy, becker type 10.1
234 sleep apnea 10.1
235 sensorineural hearing loss 10.1
236 microcephaly 10.1
237 hypogonadism 10.1
238 gm2 gangliosidosis 10.1
239 hypogonadotropism 10.1
240 48,xyyy 10.1
241 gangliosidosis 10.1
242 insulin-like growth factor i 10.1
243 amyotonia congenita 10.1
244 myopathy, congenital 10.1
245 3-methylglutaconic aciduria, type iii 10.1
246 aceruloplasminemia 10.1
247 body mass index quantitative trait locus 1 10.1
248 aspiration pneumonia 10.1
249 bone resorption disease 10.1
250 dilated cardiomyopathy 10.1
251 neuritis 10.1
252 demyelinating polyneuropathy 10.1
253 mitochondrial myopathy 10.1
254 measles 10.1
255 trpv4-associated disorders 10.1
256 cerebellar hypoplasia 10.1
257 multifocal motor neuropathy 10.1
258 hereditary neuropathies 10.1
259 pancreatic cancer 10.1
260 machado-joseph disease 10.1
261 gastroesophageal reflux 10.1
262 central core disease of muscle 10.1
263 clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly 10.1
264 facioscapulohumeral muscular dystrophy 1 10.1
265 neurofibromatosis, type iv, of riccardi 10.1
266 polykaryocytosis inducer 10.1
267 tay-sachs disease 10.1
268 muscular dystrophy, congenital, lmna-related 10.1
269 muscle hypertrophy 10.1
270 pain agnosia 10.1
271 olivopontocerebellar atrophy 10.1
272 lactic acidosis 10.1
273 essential tremor 10.1
274 chronic inflammatory demyelinating polyradiculoneuropathy 10.1
275 fatty liver disease 10.1
276 back pain 10.1
277 cerebral atrophy 10.1
278 encephalopathy 10.1
279 genetic neuromuscular disease 10.1
280 colon adenocarcinoma 10.0
281 anisocoria 10.0
282 multiple sclerosis 10.0
283 sjogren syndrome 10.0
284 multiple sclerosis 3 10.0
285 astereognosia 10.0
286 glioblastoma multiforme 10.0
287 syphilis 10.0
288 congenital syphilis 10.0
289 autoimmune disease 10.0
290 cardiac conduction defect 10.0
291 oculopharyngeal muscular dystrophy 10.0
292 spinocerebellar ataxia 1 10.0
293 osteoporosis 10.0
294 short stature-obesity syndrome 10.0
295 sudden infant death syndrome 10.0
296 graves disease 1 10.0
297 charcot-marie-tooth disease, axonal, type 2d 10.0
298 bone mineral density quantitative trait locus 3 10.0
299 allergic rhinitis 10.0
300 bone mineral density quantitative trait locus 8 10.0
301 bone mineral density quantitative trait locus 15 10.0
302 brugada syndrome 10.0
303 idiopathic scoliosis 10.0
304 respiratory allergy 10.0
305 non-alcoholic fatty liver disease 10.0
306 heart disease 10.0
307 emery-dreifuss muscular dystrophy 10.0
308 bronchopneumonia 10.0
309 chronic progressive external ophthalmoplegia 10.0
310 telangiectasis 10.0
311 ehlers-danlos syndrome 10.0
312 facial paralysis 10.0
313 oligospermia 10.0
314 hypothyroidism 10.0
315 heart septal defect 10.0
316 facial hemiatrophy 10.0
317 atrial heart septal defect 10.0
318 spondylosis 10.0
319 vaccinia 10.0
320 central core myopathy 10.0
321 rhinitis 10.0
322 hyperthyroidism 10.0
323 cataract 10.0
324 arthritis 10.0
325 encephalitis 10.0
326 pathologic nystagmus 10.0
327 hypoglycemia 10.0
328 gars1-associated axonal neuropathy 10.0
329 chromosomal triplication 10.0
330 cytokine deficiency 10.0
331 hip subluxation 10.0
332 wallerian degeneration 10.0
333 dysautonomia 10.0
334 hypertonia 10.0
335 bladder cancer 10.0
336 uremia 10.0
337 acquired immunodeficiency syndrome 10.0
338 spinal cord injury 10.0
339 arthrogryposis, distal, type 1a 9.9
340 cardiac arrhythmia 9.9
341 charcot-marie-tooth disease, demyelinating, type 1a 9.9
342 contractural arachnodactyly, congenital 9.9
343 hypertrophic neuropathy of dejerine-sottas 9.9
344 ige responsiveness, atopic 9.9
345 inclusion body myositis 9.9
346 migraine with or without aura 1 9.9
347 pectus excavatum 9.9
348 poland syndrome 9.9
349 neural tube defects 9.9
350 spondylosis, cervical 9.9
351 strabismus 9.9
352 chromosome 2q35 duplication syndrome 9.9
353 syringomyelia, noncommunicating isolated 9.9
354 down syndrome 9.9
355 arthrogryposis multiplex congenita, neurogenic type 9.9
356 fetal akinesia deformation sequence 1 9.9
357 ataxia-telangiectasia 9.9
358 hypogonadism, male 9.9
359 rhabdomyosarcoma 2 9.9
360 mcleod syndrome 9.9
361 menkes disease 9.9
362 emery-dreifuss muscular dystrophy 1, x-linked 9.9
363 aging 9.9
364 beta-thalassemia 9.9
365 chorea, childhood-onset, with psychomotor retardation 9.9
366 paralytic poliomyelitis 9.9
367 metabolic acidosis 9.9
368 atrioventricular block 9.9
369 hereditary ataxia 9.9
370 autosomal recessive non-syndromic intellectual disability 9.9
371 x-linked recessive disease 9.9
372 hypogonadotropic hypogonadism 9.9
373 thalassemia 9.9
374 nasopharyngitis 9.9
375 diaphragmatic eventration 9.9
376 glucose intolerance 9.9
377 separation anxiety disorder 9.9
378 hypoparathyroidism 9.9
379 tetanus 9.9
380 allergic hypersensitivity disease 9.9
381 male infertility 9.9
382 nephrocalcinosis 9.9
383 locked-in syndrome 9.9
384 quadriplegia 9.9
385 choreatic disease 9.9
386 porphyria 9.9
387 hyperparathyroidism 9.9
388 azoospermia 9.9
389 ventricular septal defect 9.9
390 impotence 9.9
391 cerebral palsy 9.9
392 hyperinsulinism 9.9
393 neuroaxonal dystrophy 9.9
394 astrocytoma 9.9
395 lipid metabolism disorder 9.9
396 nemaline myopathy 9.9
397 demyelinating disease 9.9
398 rhabdomyosarcoma 9.9
399 syringomyelia 9.9
400 liver disease 9.9
401 hyperglycemia 9.9
402 movement disease 9.9
403 infertility 9.9
404 sleep disorder 9.9
405 dystonia 9.9
406 congestive heart failure 9.9
407 severe combined immunodeficiency 9.9
408 combined t cell and b cell immunodeficiency 9.9
409 adenoma 9.9
410 progressive bulbar palsy 9.9
411 osteoarthritis 9.9
412 polyhydramnios 9.9
413 learning disability 9.9
414 mechanical strabismus 9.9
415 diabetes mellitus 9.9
416 hypereosinophilic syndrome 9.9
417 riboflavin transporter deficiency neuronopathy 9.9
418 polymyositis 9.9
419 spastic paraparesis 9.9
420 posttransplant acute limbic encephalitis 9.9
421 periodic paralysis 9.9
422 hepatocellular carcinoma 9.9
423 triiodothyronine receptor auxiliary protein 9.9
424 cystinosis, nephropathic 9.9
425 immune deficiency disease 9.9
426 ocular motor apraxia 9.9
427 body mass index quantitative trait locus 11 9.9
428 cystinosis 9.9
429 hepatic coma 9.9
430 hepatic encephalopathy 9.9
431 toxic shock syndrome 9.9
432 critical illness polyneuropathy 9.9
433 gonadal dysgenesis 9.9
434 turner syndrome 9.9
435 pancreatic ductal adenocarcinoma 9.9
436 crohn's disease 9.9
437 fasting hypoglycemia 9.9
438 parsonage turner syndrome 9.9
439 rapidly involuting congenital hemangioma 9.9
440 premature aging 9.9
441 acanthosis nigricans 9.7
442 candidiasis, familial, 1 9.7
443 carpal tunnel syndrome 9.7
444 cervical rib 9.7
445 seizures, benign familial neonatal, 1 9.7
446 dupuytren contracture 9.7
447 fibrosis of extraocular muscles, congenital, 1 9.7
448 gilles de la tourette syndrome 9.7
449 hair whorl 9.7
450 hypertriglyceridemia, familial 9.7
451 lentigines 9.7
452 lipomatosis, multiple 9.7
453 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 1 9.7
454 myoclonus and ataxia 9.7
455 neurofibromatosis, type i 9.7
456 neuropathy, hereditary sensory and autonomic, type ia 9.7
457 papillomatosis, confluent and reticulated 9.7
458 parkinson disease, late-onset 9.7
459 perry syndrome 9.7
460 hypokalemic periodic paralysis, type 1 9.7
461 pheochromocytoma 9.7
462 porphyria, acute intermittent 9.7
463 prader-willi syndrome 9.7
464 prostate cancer 9.7
465 protoporphyria, erythropoietic, 1 9.7
466 dowling-degos disease 1 9.7
467 retinal detachment 9.7
468 retinoblastoma 9.7
469 rheumatoid arthritis 9.7
470 roussy-levy hereditary areflexic dystasia 9.7
471 emery-dreifuss muscular dystrophy 2, autosomal dominant 9.7
472 spinal arachnoiditis 9.7
473 spinocerebellar ataxia 2 9.7
474 spondylolisthesis 9.7
475 digeorge syndrome 9.7
476 torticollis 9.7
477 vitiligo-associated multiple autoimmune disease susceptibility 6 9.7
478 abetalipoproteinemia 9.7
479 chiari malformation type ii 9.7
480 charge syndrome 9.7
481 cryptorchidism, unilateral or bilateral 9.7
482 cystinuria 9.7
483 mitochondrial complex iv deficiency 9.7
484 leukoencephalopathy, hereditary diffuse, with spheroids 9.7
485 neuropathy, hereditary sensory and autonomic, type iii 9.7
486 friedreich ataxia 9.7
487 glycogen storage disease ii 9.7
488 hydrocephalus, congenital, 1 9.7
489 hydrops fetalis, nonimmune 9.7
490 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 9.7
491 lambert syndrome 9.7
492 leprosy 3 9.7
493 marden-walker syndrome 9.7
494 lethal congenital contracture syndrome 1 9.7
495 myeloma, multiple 9.7
496 gyrate atrophy of choroid and retina 9.7
497 phenylketonuria 9.7
498 pierre robin syndrome 9.7
499 retinitis pigmentosa 9.7
500 rothmund-thomson syndrome, type 2 9.7
501 androgen insensitivity syndrome 9.7
502 adrenoleukodystrophy 9.7
503 combined oxidative phosphorylation deficiency 6 9.7
504 occipital horn syndrome 9.7
505 pelizaeus-merzbacher disease 9.7
506 rett syndrome 9.7
507 frontotemporal dementia 9.7
508 supranuclear palsy, progressive, 1 9.7
509 stroke, ischemic 9.7
510 peroxisome biogenesis disorder 1b 9.7
511 yemenite deaf-blind hypopigmentation syndrome 9.7
512 chromosome 18q deletion syndrome 9.7
513 muscular dystrophy, congenital, megaconial type 9.7
514 myotonic dystrophy 2 9.7
515 brittle bone disorder 9.7
516 cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1 9.7
517 nonaka myopathy 9.7
518 rippling muscle disease 2 9.7
519 meningioma, radiation-induced 9.7
520 charcot-marie-tooth disease, dominant intermediate b 9.7
521 charcot-marie-tooth disease, dominant intermediate a 9.7
522 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
523 amyotrophic lateral sclerosis 3 9.7
524 meningioma, familial 9.7
525 slowed nerve conduction velocity, autosomal dominant 9.7
526 amyotrophic lateral sclerosis 8 9.7
527 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 2 9.7
528 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 9.7
529 b-cell immunodeficiency, distal limb anomalies, and urogenital malformations 9.7
530 epileptic encephalopathy, early infantile, 3 9.7
531 cortical dysplasia, complex, with other brain malformations 7 9.7
532 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 4 9.7
533 diabetes mellitus, ketosis-prone 9.7
534 microvascular complications of diabetes 3 9.7
535 microvascular complications of diabetes 4 9.7
536 microvascular complications of diabetes 6 9.7
537 microvascular complications of diabetes 7 9.7
538 fatty liver disease, nonalcoholic 1 9.7
539 charcot-marie-tooth disease, axonal, type 2o 9.7
540 pontocerebellar hypoplasia, type 1b 9.7
541 membranous nephropathy 9.7
542 alacrima, achalasia, and mental retardation syndrome 9.7
543 poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis 9.7
544 carbonic anhydrase va deficiency, hyperammonemia due to 9.7
545 charcot-marie-tooth disease, axonal, type 2z 9.7
546 myopathy, scapulohumeroperoneal 9.7
547 hydrops, lactic acidosis, and sideroblastic anemia 9.7
548 arthrogryposis, distal, with impaired proprioception and touch 9.7
549 angina pectoris 9.7
550 deficiency anemia 9.7
551 pulmonary hypertension 9.7
552 congenital hypothyroidism 9.7
553 hypophosphatemia 9.7
554 periventricular nodular heterotopia 9.7
555 exudative vitreoretinopathy 9.7
556 hereditary sensory neuropathy 9.7
557 alcohol-related neurodevelopmental disorder 9.7
558 fatal infantile cardioencephalomyopathy due to cytochrome c oxidase deficiency 9.7
559 autosomal genetic disease 9.7
560 adrenal gland pheochromocytoma 9.7
561 sexual disorder 9.7
562 aphasia 9.7
563 diffuse alopecia areata 9.7
564 basal ganglia calcification 9.7
565 stuttering 9.7
566 recessive dystrophic epidermolysis bullosa 9.7
567 thrombosis 9.7
568 mitochondrial dna depletion syndrome 9.7
569 bone disease 9.7
570 congenital fiber-type disproportion 9.7
571 polycystic kidney disease 9.7
572 autosomal dominant limb-girdle muscular dystrophy 9.7
573 tabes dorsalis 9.7
574 neuroretinitis 9.7
575 osteomyelitis 9.7
576 pleomorphic lipoma 9.7
577 dermatomyositis 9.7
578 mumps 9.7
579 leukodystrophy 9.7
580 pre-eclampsia 9.7
581 rickets 9.7
582 meningocele 9.7
583 hypospadias 9.7
584 hydrocephalus 9.7
585 amnestic disorder 9.7
586 hemiplegia 9.7
587 neonatal respiratory failure 9.7
588 primary hyperparathyroidism 9.7
589 microcytic anemia 9.7
590 rabies 9.7
591 spinal meningioma 9.7
592 hypertensive heart disease 9.7
593 polycystic ovary syndrome 9.7
594 myopia 9.7
595 conn's syndrome 9.7
596 inflammatory spondylopathy 9.7
597 hemosiderosis 9.7
598 neurogenic bladder 9.7
599 arachnoiditis 9.7
600 neutropenia 9.7
601 secondary hyperparathyroidism 9.7
602 guillain-barre syndrome 9.7
603 dementia 9.7
604 exophthalmic ophthalmoplegia 9.7
605 gout 9.7
606 color blindness 9.7
607 eclampsia 9.7
608 sapho syndrome 9.7
609 autoimmune polyendocrine syndrome 9.7
610 postencephalitic parkinson disease 9.7
611 dracunculiasis 9.7
612 candidiasis 9.7
613 panniculitis 9.7
614 lymphadenitis 9.7
615 pneumothorax 9.7
616 vascular disease 9.7
617 status epilepticus 9.7
618 hyperostosis 9.7
619 chronic mucocutaneous candidiasis 9.7
620 myotonia congenita 9.7
621 ankylosis 9.7
622 craniosynostosis 9.7
623 epidermolysis bullosa 9.7
624 skin atrophy 9.7
625 bilirubin metabolic disorder 9.7
626 testicular cancer 9.7
627 lipomatosis 9.7
628 lysosomal storage disease 9.7
629 tracheal stenosis 9.7
630 central nervous system disease 9.7
631 unverricht-lundborg syndrome 9.7
632 retinitis 9.7
633 congenital myasthenic syndrome 9.7
634 brachial plexus neuropathy 9.7
635 plasmacytoma 9.7
636 cranial nerve palsy 9.7
637 intestinal pseudo-obstruction 9.7
638 insulinoma 9.7
639 systemic scleroderma 9.7
640 hypertrichosis 9.7
641 radiculopathy 9.7
642 dyslexia 9.7
643 secretory meningioma 9.7
644 lymphoplasmacyte-rich meningioma 9.7
645 holoprosencephaly 9.7
646 familial retinoblastoma 9.7
647 benign ependymoma 9.7
648 epidermolysis bullosa dystrophica 9.7
649 liver cirrhosis 9.7
650 copper deficiency myelopathy 9.7
651 plexiform neurofibroma 9.7
652 pituitary gland disease 9.7
653 cellular ependymoma 9.7
654 pneumonia 9.7
655 spinal cancer 9.7
656 inferior myocardial infarction 9.7
657 bronchitis 9.7
658 viral encephalitis 9.7
659 inherited metabolic disorder 9.7
660 spondylitis 9.7
661 anterior spinal artery syndrome 9.7
662 cerebrovascular disease 9.7
663 b-cell lymphoma 9.7
664 parathyroid adenoma 9.7
665 placenta disease 9.7
666 myocarditis 9.7
667 peritonitis 9.7
668 ileus 9.7
669 retinal degeneration 9.7
670 herpes simplex 9.7
671 nervous system disease 9.7
672 vasculitis 9.7
673 chickenpox 9.7
674 rubella 9.7
675 progressive myoclonus epilepsy 9.7
676 macroglobulinemia 9.7
677 amyloidosis 9.7
678 central sleep apnea 9.7
679 hypopituitarism 9.7
680 intracranial hypertension 9.7
681 neurofibroma 9.7
682 congenital nystagmus 9.7
683 diabetic neuropathy 9.7
684 alopecia 9.7
685 hypoplastic left heart syndrome 9.7
686 albinism 9.7
687 muscular dystrophy, duchenne and becker type 9.7
688 dysferlinopathy 9.7
689 dystrophinopathies 9.7
690 exosc3-related pontocerebellar hypoplasia 9.7
691 flna-related periventricular nodular heterotopia 9.7
692 hypermobile ehlers-danlos syndrome 9.7
693 hypertrophic cardiomyopathy 9.7
694 mitochondrial disorders 9.7
695 tk2-related mitochondrial dna maintenance defect, myopathic form 9.7
696 tubulinopathies 9.7
697 adrenomyeloneuropathy 9.7
698 aminoaciduria 9.7
699 atrial septal defect coronary sinus 9.7
700 boerhaave syndrome 9.7
701 cerebellar degeneration 9.7
702 chiari malformation 9.7
703 chromosome 9p duplication 9.7
704 coccygodynia 9.7
705 congenital muscular dystrophy due to dystroglycanopathy 9.7
706 distal myopathy with vocal cord weakness 9.7
707 growth hormone deficiency 9.7
708 hansen's disease 9.7
709 lipogranulomatosis 9.7
710 myoclonus epilepsy 9.7
711 neonatal adrenoleukodystrophy 9.7
712 ornithinemia 9.7
713 tracheobronchomalacia 9.7
714 abdominal wall defect 9.7
715 color vision deficiency 9.7
716 dementia - subcortical 9.7
717 fainting 9.7
718 hypersomnia 9.7
719 hypoxia 9.7
720 infantile hypotonia 9.7
721 myopathy - thyrotoxic 9.7
722 neuronal migration disorders 9.7
723 paresthesia 9.7
724 spinocerebellar degeneration 9.7
725 swallowing disorders 9.7
726 syncope 9.7
727 kenny-caffey syndrome 9.7
728 nevus of ota 9.7
729 neurenteric cyst 9.7
730 qualitative or quantitative defects of dystrophin 9.7
731 qualitative or quantitative defects of dysferlin 9.7
732 temporomandibular joint anomaly 9.7
733 specific language disorder 9.7
734 rare hereditary hemochromatosis 9.7
735 acute sensory ataxic neuropathy 9.7
736 qualitative or quantitative defects of alpha-dystroglycan 9.7
737 argyria 9.7
738 b-cell immunodeficiency-limb anomaly-urogenital malformation syndrome 9.7
739 paternal uniparental disomy 9.7
740 rare surgical neurologic disease 9.7
741 overgrowth syndrome 9.7
742 autoinflammatory syndrome 9.7
743 vitreoretinopathy 9.7
744 laminopathy 9.7
745 acquired motor neuron disease 9.7
746 polyendocrinopathy 9.7
747 spondyloarthropathy 1 9.7
748 colorectal cancer 9.7
749 esophageal cancer 9.7
750 renal cell carcinoma, nonpapillary 9.7
751 myelopathy, htlv-1-associated 9.7
752 myopathy, tubular aggregate, 1 9.7
753 multiple endocrine neoplasia, type iib 9.7
754 optic atrophy 1 9.7
755 hyperkalemic periodic paralysis 9.7
756 pulmonary hypertension, primary, 1 9.7
757 acyl-coa dehydrogenase, short-chain, deficiency of 9.7
758 takayasu arteritis 9.7
759 lung cancer 9.7
760 glycogen storage disease iii 9.7
761 muscular dystrophy, limb-girdle, autosomal recessive 1 9.7
762 muscular dystrophy, limb-girdle, autosomal recessive 2 9.7
763 miyoshi muscular dystrophy 1 9.7
764 leigh syndrome 9.7
765 hemophilia b 9.7
766 brody myopathy 9.7
767 body mass index quantitative trait locus 9 9.7
768 body mass index quantitative trait locus 8 9.7
769 body mass index quantitative trait locus 4 9.7
770 body mass index quantitative trait locus 10 9.7
771 body mass index quantitative trait locus 7 9.7
772 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
773 body mass index quantitative trait locus 12 9.7
774 body mass index quantitative trait locus 14 9.7
775 leukemia, acute lymphoblastic 9.7
776 cholangitis, primary sclerosing 9.7
777 charcot-marie-tooth disease, dominant intermediate e 9.7
778 body mass index quantitative trait locus 18 9.7
779 cholangiocarcinoma 9.7
780 body mass index quantitative trait locus 19 9.7
781 body mass index quantitative trait locus 20 9.7
782 peripheral vascular disease 9.7
783 hyperphosphatemia 9.7
784 polycystic liver disease 9.7
785 renal fibrosis 9.7
786 colorectal adenocarcinoma 9.7
787 hereditary sensory and autonomic neuropathy type 1 9.7
788 non-alcoholic steatohepatitis 9.7
789 lymphocytic leukemia 9.7
790 portal hypertension 9.7
791 spastic diplegia 9.7
792 adult respiratory distress syndrome 9.7
793 autonomic neuropathy 9.7
794 protein-energy malnutrition 9.7
795 mononeuropathy 9.7
796 acute leukemia 9.7
797 lagophthalmos 9.7
798 cholestasis 9.7
799 sclerosing cholangitis 9.7
800 rectum cancer 9.7
801 kidney cancer 9.7
802 dermatitis 9.7
803 glycogen storage disease 9.7
804 idiopathic interstitial pneumonia 9.7
805 adenocarcinoma 9.7
806 interstitial lung disease 9.7
807 tropical spastic paraparesis 9.7
808 pulmonary fibrosis 9.7
809 arthropathy 9.7
810 intrahepatic cholangiocarcinoma 9.7
811 ureteral obstruction 9.7
812 aortic valve insufficiency 9.7
813 t-cell leukemia 9.7
814 localized scleroderma 9.7
815 chronic fatigue syndrome 9.7
816 ulcerative colitis 9.7
817 subacute delirium 9.7
818 hepatopulmonary syndrome 9.7
819 achalasia 9.7
820 cholangitis 9.7
821 fasciitis 9.7
822 htlv-1 associated myelopathy/tropical spastic paraparesis 9.7
823 human t-cell leukemia virus type 1 9.7
824 pseudobulbar affect 9.7
825 aneurysm 9.7
826 progeroid syndrome 9.7
827 early-onset generalized limb-onset dystonia 9.7
828 acyl-coa dehydrogenase deficiency 9.7
829 aids wasting syndrome 9.7
830 skeletal muscle disease 9.7

Graphical network of the top 20 diseases related to Muscular Atrophy:



Diseases related to Muscular Atrophy

Symptoms & Phenotypes for Muscular Atrophy

UMLS symptoms related to Muscular Atrophy:


muscle weakness, myokymia, muscular fasciculation, muscle cramp, spasm, neuromuscular manifestations

GenomeRNAi Phenotypes related to Muscular Atrophy according to GeneCards Suite gene sharing:

26 (showing 8, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.1 VRK1
2 Decreased viability GR00221-A-2 10.1 VRK1
3 Decreased viability GR00221-A-4 10.1 VRK1
4 Decreased viability GR00240-S-1 10.1 ASAH1 SMN2
5 Decreased viability GR00301-A 10.1 VRK1
6 Decreased viability GR00381-A-1 10.1 ASAH1 UBA1
7 Decreased viability GR00402-S-2 10.1 AR ASAH1 ATP2B3 ATP7A BICD2 DNAJB2
8 no effect GR00402-S-1 9.62 AR ASAH1 ATP2B3 ATP7A BICD2 DNAJB2

MGI Mouse Phenotypes related to Muscular Atrophy:

45 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.28 AR ATP7A DYNC1H1 GARS1 IGHMBP2 PLEKHG5

Drugs & Therapeutics for Muscular Atrophy

Drugs for Muscular Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 298, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
3
Fosinopril Approved Phase 4 98048-97-6 55891
4
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Sodium citrate Approved, Investigational Phase 4 68-04-2
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
11
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
12
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
13
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
14
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
15 Neurotransmitter Agents Phase 4
16 Anticonvulsants Phase 4
17 Antihypertensive Agents Phase 4
18 Angiotensin-Converting Enzyme Inhibitors Phase 4
19 Excitatory Amino Acid Antagonists Phase 4
20 Excitatory Amino Acids Phase 4
21 Excitatory Amino Acid Agonists Phase 4
22 Antipyretics Phase 4
23 Analgesics, Non-Narcotic Phase 4
24 Hormone Antagonists Phase 4
25 Hormones Phase 4
26 glucocorticoids Phase 4
27 Protective Agents Phase 4
28 Antineoplastic Agents, Hormonal Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Neuroprotective Agents Phase 4
31 Citrate Phase 4
32 Vasodilator Agents Phase 4
33 Phosphodiesterase 5 Inhibitors Phase 4
34 Sildenafil Citrate Phase 4 171599-83-0
35 Phosphodiesterase Inhibitors Phase 4
36 Gastrointestinal Agents Phase 4
37 Autonomic Agents Phase 4
38 Methylprednisolone Acetate Phase 4
39 Antiemetics Phase 4
40
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
41
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
42
Ketoprofen Approved, Vet_approved Phase 3 22071-15-4 3825
43
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
44
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
45
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
46
Miglustat Approved Phase 3 72599-27-0 51634
47
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
48
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
49
Testosterone Approved, Experimental, Investigational Phase 2, Phase 3 58-22-0, 481-30-1 6013 10204
50
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3 5949-44-0
51
Testosterone enanthate Approved Phase 2, Phase 3 315-37-7 9416
52
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
53
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
54
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
55
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3 303-98-0 5281915
56
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
57
1-Deoxynojirimycin Investigational Phase 3 19130-96-2 1374
58 Tranquilizing Agents Phase 3
59 GABA Agents Phase 3
60 Antimanic Agents Phase 3
61 Antibodies, Monoclonal Phase 2, Phase 3
62 Antibodies, Blocking Phase 2, Phase 3
63 taxane Phase 3
64 Vitamin B 12 Phase 2, Phase 3
65 Vitamin B Complex Phase 2, Phase 3
66 Vitamin B12 Phase 2, Phase 3
67 Vitamin B9 Phase 2, Phase 3
68 Folate Phase 2, Phase 3
69 Antiviral Agents Phase 3
70 Anti-Retroviral Agents Phase 3
71 Glycoside Hydrolase Inhibitors Phase 3
72 Cardiac Glycosides Phase 3
73 Anti-HIV Agents Phase 3
74 Pharmaceutical Solutions Phase 2, Phase 3
75 Anabolic Agents Phase 2, Phase 3
76 Testosterone 17 beta-cypionate Phase 2, Phase 3
77 Androgens Phase 2, Phase 3
78 Micronutrients Phase 3
79 Vitamins Phase 3
80 Trace Elements Phase 3
81 Nutrients Phase 3
82 Ubiquinone Phase 3
83 insulin Phase 2, Phase 3
84 Insulin, Globin Zinc Phase 2, Phase 3
85 Hypoglycemic Agents Phase 2, Phase 3
86
Etodolac Approved, Investigational, Vet_approved Phase 2 41340-25-4 3308
87
Propranolol Approved, Investigational Phase 2 525-66-6 4946
88
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
89
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
90
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
91
Levetiracetam Approved Phase 2 102767-28-2 441341
92
Mecasermin Approved, Investigational Phase 1, Phase 2 68562-41-4
93
Dutasteride Approved, Investigational Phase 2 164656-23-9 152945 6918296
94
Infliximab Approved Phase 2 170277-31-3
95
Finasteride Approved Phase 2 98319-26-7 57363
96
Methimazole Approved Phase 2 60-56-0 1349907
97
Ursodeoxycholic acid Approved, Investigational Phase 2 128-13-2 31401
98
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
99
Amifampridine Approved, Investigational Phase 2 54-96-6 5918
100
4-Aminopyridine Approved Phase 1, Phase 2 504-24-5 1727
101
Tesamorelin Approved, Investigational Phase 2 218949-48-5
102
Melatonin Approved, Nutraceutical, Vet_approved Phase 2 73-31-4 896
103
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140